Coronavirus disease 2019 in Latin American patients with multiple sclerosis

Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragoso, Yara D., Schiavetti, Irene, Carmisciano, Luca, Ponzano, Marta, Steinberg, Judith, Treviño-Frenk, Irene, Ciampi, Ethel, Vecino, Maria Cecilia A., Correa, Edgar P., Carcamo, Claudia, Gomes, Sidney, Pimentel, Maria Lucia V., Santos, Gutemberg A.C., Vrech, Carlos, Winckler, Thereza C.A., Sormani, Maria Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310568/
https://www.ncbi.nlm.nih.gov/pubmed/34332462
http://dx.doi.org/10.1016/j.msard.2021.103173
Descripción
Sumario:Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associated to hospitalization and death. Despite the small sample size, this study highlights the awareness regarding therapeutic options for MS during the pandemic.

Ejemplares similares